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Background: Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment for patients with
metastatic neuroendocrine tumors (NETs). However, delivering sufficient radiation dose to the tumor to result in a
high percentage of long-term tumor remissions remains challenging because of the limits imposed on administered
activity levels by radiation damage to normal tissues. The goal of this study was to evaluate the dosimetric
advantages of adding 131I meta-iodobenzylguanidine (131I-MIBG) to 90Y DOTA Phe1-Tyr3-octreotide (90Y-DOTATOC)
in patients with advanced stage midgut NETs.
Methods: Ten patients were imaged simultaneously with 131I-MIBG and 111In-pentetreotide (as a surrogate for
90Y-DOTATOC) on days 1, 2, and 3 post-administration. Blood samples were obtained at the same time points.
Using dosimetry measures from this data and our previously published methodology for calculating optimal
combined administered activity levels for therapy, we determined the amount of 131I-MIBG that could be added to
90Y-DOTATOC without exceeding normal organ dose limits (marrow and kidneys) along with the expected increase
in associated tumor dose, if any.
Results: We found that a median value of 34.6 GBq of 131I-MIBG could be safely added to 90Y-DOTATOC (delivered
over multiple cycles) by reducing the maximum total deliverable 90Y-DOTATOC by a median value of 24.5%. Taking
this treatment approach, we found that there would be a median increase in deliverable tumor dose of 4,046 cGy
in six of the ten subjects. Of note, there were a small number of metastases that were positive for only one or the
other of these radiopharmaceuticals within the same subject.
Conclusions: We conclude that approximately half of the patients with midgut NETs that are eligible for PRRT
could reasonably be expected to benefit from the addition of 131I-MIBG to 90Y-DOTATOC.
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Peptide receptor radionuclide therapy (PRRT) is well estab-
lished as an effective form of treatment for patients with
metastatic neuroendocrine tumors (NETs) delivering modest
objective response rates but notable symptomatic and prob-
able survival benefits [1-3]. PRRT with either 90Y DOTA
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is recommended by the European and North American
neuroendocrine tumor societies for the treatment of
patients with non-operable refractory disease [4-6]
90Y-DOTATOC has shown significant efficacy as a
therapeutic agent in patients with metastatic neuroen-
docrine tumors [7-10]. However, delivering sufficient
radiation dose to the tumors to result in a high percent-
age of long-term remissions remains challenging be-
cause of the limits imposed on administered activity
levels by radiation damage to normal tissues. For
90Y-DOTATOC, the radiation dose to kidneys limitsan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Imaging/biodistribution data collection schedule




Blood samples X (1 and 4 h) X X
Whole-body conjugate views X X X
SPECT X X X
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patient.
131I meta-iodobenzylguanidine (131I-MIBG) is well
known as an effective form of therapy for advanced stage
pheochromocytomes or neuroblastomas [11,12]. In
addition, there is good evidence that 131I-MIBG can be
an effective treatment for certain patients with gastro-
enteropancreatic NETs [13,14]. Significant tumor uptake
of MIBG is reported in over 50% of patients with NETs
of midgut origin [15-17]. In contrast to 90Y-DOTATOC,
toxicity to bone marrow limits the level of administered
activity that can be delivered with 131I-MIBG. In addition,
the tumor targeting mechanism is distinctly different for
MIBG. We have previously demonstrated both conceptu-
ally and mathematically that this difference in the toxicity
and biodistribution profiles for these two radioactive drugs
allows us to combine large fractions of the individually de-
liverable maximum tolerated administered activity of each
radioactive drug into a single treatment regimen yielding
potentially higher tumor radiation doses without exceed-
ing normal organ dose limits [18,19].
There are three potential advantages to adding 131I-MIBG
to PRRT with 90Y-DOTATOC for the treatment of neuro-
endocrine tumors as opposed to using PRRT alone. First of
all, as noted above, our preliminary work indicates that it
should be possible to notably increase the delivered tumor
radiation dose beyond that achievable with 90Y-DOTATOC
alone in some patients with neuroendocrine tumors that
also concentrate MIBG [18]. Secondly, because of the dif-
ferent tumor targeting mechanisms for MIBG and octreo-
tide, it may be possible to achieve therapeutic radiation
delivery to a greater number of tumor cells or tumor sites
than with only 90Y-DOTATOC [20,21]. And thirdly, studies
have demonstrated that there is an advantage to using a
combination of radioactive drugs that have different beta
particle energies to treat metastatic lesions when they vary
significantly in size [22].
The overall goal of this study was to investigate the
feasibility and advantages of combining 131I-MIBG
with 90Y-DOTATOC to treat NETs compared to treat-
ment with 90Y-DOTATOC alone through the use of
pre-therapy biodistribution and dosimetry results. The
importance of this type of approach using the theranos-
tics concept to manage patients with NETs has been
recently emphasized [23].
The specific goals were (1) to determine in what frac-
tion of patients with midgut NETs a substantial amount
of 131I-MIBG could be safely added to 90Y-DOTATOC
without exceeding normal organ dose limits, (2) to de-
termine whether tumor radiation dose levels could
be increased by more than 30% through addition of
131I-MIBG to 90Y-DOTATOC, and (3) to determine if
additional tumor sites would be targeted through the
addition of 131I-MIBG.Methods
This was a prospective study of patients with metastatic
or otherwise non-operable neuroendocrine tumors of
midgut origin. All patients were required to have a
serum creatinine level of less than 2.0 mg/dl and were
excluded if they had undergone prior PRRT.
All subjects underwent imaging (and blood sampling)
with tracer amounts of 131I-MIBG and 111In-pentetreotide
for purposes of determining individualized radiation dose
levels per unit of administered activity to the kidneys,
marrow, and select tumor sites. Patients were not allowed
to use their short-acting Sandostatin (Sandoz GmbH,
Schaftenau, Austria) beginning 12 h prior to day 1 of the
study until completion of imaging and were required to be
at least 21 days out from their last Sandostatin LAR injec-
tion (Sandoz GmbH). Subjects did not receive cationic
amino acid infusions. Rather, we built into our model a
20% reduction in renal radiation dose from 90Y-DOTATOC
reflecting what is known to occur with the use of a
cationic amino acid infusion during an actual 90Y-DOTATOC
treatment [24].
Each subject underwent multiple imaging sessions
over a 3-day period following radiopharmaceutical ad-
ministration as outlined in Table 1. Each subject re-
ceived 0.5 mCi (first two subjects enrolled) or 1.0 mCi of
131I-MIBG plus 5 to 6 mCi of 111In-pentetreotide intra-
venously within a few minutes of each other. All scinti-
graphic imaging studies were acquired as multi-isotope
studies with a 20% window on the 364-keV photopeak of
131I and the 247- and 172-keV photopeaks of 111In. High
energy collimation, appropriate for 131I, was used for all
simultaneous imaging studies. Anterior and posterior
planar whole-body images along with single photon
emission computed tomography (SPECT) studies of the
chest/abdomen/pelvis were obtained at (nominally) 4,
24, and 48 h after injection. Beyond 48 h, clearance data
for blood, kidneys, and selected tumors was based on ex-
trapolation of the curve from the 24- and 48-h time
points. Standard sources of 131I and 111In with an activ-
ity of 1 to 2 mBq were placed within the field of view at
each image acquisition session. Contrast enhanced com-
puted tomography (CT) images of the chest, abdomen,
and pelvis were obtained if the subject had not had a re-
cent diagnostic CT exam (within 6 months).
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image data as well as the blood samples assayed on the well
counter. For the well counter measurements, the down-
scatter fraction of counts from the 131I 364-keV gamma
rays into the 111In energy windows was determined to be
0.25. An additional up-scatter component correction (0.67)
had to be made because of the strong coincidence sum
peak associated with the In-111 172- and 254-keV cascade.
For the image data, the down-scatter fraction was approxi-
mately 0.15. Because of the high ratio of administered activ-
ity of 111In-pentetreotide to 131I-MIBG and the much
higher detection efficiency for the 111In gamma rays, down-
scatter corrections were essentially negligible.
The patient-specific kinetic and biodistribution results
from the concurrent tracer studies with 131I-MIBG and
111In-pentetreotide were then used to calculate values
for radiation dose per total administered activity (mGy/
MBq) for marrow, kidneys, and selected tumors for both
131I-MIBG and 90Y-DOTATOC. Dosimetry calculations
were based on the conjugate view methodology for
kidneys and tumor sites applying patient-specific renal
mass as measured by CT for each individual. CT was
also used to determine tumor volume/mass. A represen-
tative soft tissue metastasis with well-defined borders of
at least 2 cm in diameter on CT was selected from each
subject for dosimetry calculations when there was visible
tumor uptake with both 131I-MIBG and 111In-pentetreotide.
Bone marrow dose calculations were based on clearance
and activity measures from the blood samples. We assumed
a 1:1 ratio of activity in the blood relative to the bone
marrow for each radiopharmaceutical. The tumor, blood,
and kidney doses were estimated using first principle
methods originally described by Quimby and incorporated
into the MIRD/OLINDA formulations [25]. The total inte-
grated activity was multiplied by the average emitted energy
modified by the appropriate absorption factors divided by
the tissue mass. For dose estimates with 90Y and the beta
component of 131I, the absorbed fraction was assumed
to be 1 for activity located within the tissue under
consideration and 0 from all external sources.
The patient-specific dosimetry values for marrow and
kidneys for each subject were then used with our previously
described methods to calculate the maximum safe adminis-
trable activity for 90Y-DOTATOC when given alone and
then for each of the two radiopharmaceuticals when given
in combination using previously described methods [18].
To make these calculations requires setting upper limits for
total radiation dose to an individual's bone marrow and kid-
neys from such a treatment. In this study, we used a limit
of 2,300 cGy for the kidneys and 300 cGy for bone marrow.
Although 300 cGy for a marrow upper limit would be high
for a single non-myeloablative treatment, in practice, this
dose would be spread over two or three individual treat-
ment cycles (every 8 to 10 weeks to allow for marrowrecovery) leading to a marrow dose per cycle of a very rea-
sonable 100 to 150 cGy. Finally, adding the tumor dosim-
etry results to the patient's renal and marrow results in the
model allowed us to calculate the expected increase, if any,
in tumor dose from a combined therapy.
Results
There were a total of ten subjects in this study. The me-
dian patient age was 58 years (range 37 to 76 years). There
were six men and four women. All subjects had confirmed
midgut NETs. At least one soft tissue metastatic lesion
was present in all subjects and identifiable on correspond-
ing CT upon entry into the study. Nine of the ten subjects
had metastatic disease in the liver, while one individual
had metastatic disease present only in two large abdom-
inal nodal masses. One patient with liver metastases also
had a metastatic lung lesion, and another patient with liver
metastases had metastatic lesions in both breasts.
Planar and SPECT 111In-pentetreotide images were
positive for at least one metastatic site in all ten subjects.
131I-MIBG planar and SPECT imaging were both positive
for metastatic disease in six of the ten subjects. Tumor
dosimetry was therefore performed in these six subjects,
specifically on a liver metastasis in four subjects and on an
abdominal nodal mass in one subject and a large breast
metastasis in one subject. 131I-MIBG and 111In-pentetreotide
tumor uptake pattern concordance (or discordance) for each
subject is given in the first column of Table 2. Table 3
provides a summary of individual lesion MIBG and pente-
treotide uptake status for these six subjects. As seen in this
table, the majority of the soft tissue metastases were visually
positive with both agents. However, there were a notable
number of lesions that were positive with MIBG only and
showed a pattern of complete concordance for metastatic
disease with the corresponding 111In-pentetreotide images
in two of these six subjects. In the other four cases, the
pattern of tumor uptake was modestly discordant not only
showing metastases (predominately hepatic) that were
MIBG positive and octreotide positive but also showing 1
to 2 tumor sites in each case that were 131I-MIBG positive
but 111In-pentetreotide negative and vice versa. Figure 1
depicts one of the study patients with multiple hepatic
metastases, the majority of which concentrated both
radiopharmaceuticals. However, this individual also had
two hepatic lesions which only demonstrated uptake
with MIBG (one of which is depicted in the image).
Excluding the 4 subjects where MIBG imaging was
entirely negative, there were a total of 7 MIBG-positive/
octreotide-negative lesions, 8 MIBG-negative/octreotide-
positive lesions, and 22 MIBG-positive/octreotide-positive
metastatic lesions.
For the six MIBG-positive subjects, the mean value for
maximum administrable activity of 90Y-DOTATOC was
found to be 11.8 GBq (standard deviation (S.D.) =


























1 Concordant 13.5 72 32.2 1,623 7,618
2 All tumors MIBG
negative
3 All tumors MIBG
negative
4 Discordant 11.1 88 29.8 3,317 11,119
5 All tumors MIBG
negative
6 Discordant 14.4 16 42.8 10,330 45,737
7 Discordant 19.8 100 0.0 14,068 14,068
8 Discordant 4.9 75 33.3 1,006 2,499
9 Concordant 7.2 76 45.0 729 2,829






N/A 10.7 85 36.4 4,685 14,555
Total renal limit, 23 Gy; total marrow limit, 3 Gy. N/A, not applicable. aResults in this row were calculated using average dose values for the marrow, kidneys, and
NETs from the literature.
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delivered over several individual treatment cycles. We cal-
culated that it would be ‘safe’ (not exceed normal organ
limits) for these six subjects to concurrently receive a
mean value of 30.0 GBq (S.D. = 14.8 GBq) of 131I-MIBG
by reducing the total administered 90Y-DOTATOC activity
by a mean value of 26% (S.D. = 27%). The increase in
tumor dose to a representative tumor site achievable by
adding 131I-MIBG to 90Y-DOTATOC in these six subjects
ranged from 0 to 35,407 cGy with a median increase of
4,046 cGy and mean increase of 8,799 cGy (S.D. =
12,196 cGy). This additional tumor dose represents an in-
crease of 169% over the mean tumor dose calculated for
maximum 90Y-DOTATOC when given alone (5,180 cGy).
The data for each individual subject is presented in Table 2.
We also performed the calculations using reported dosi-
metry results from the literature for the kidney, marrow,
and tumor for 131I-MIBG and 90Y-DOTATOC [26-29].
These results are also given in the last row of Table 2.
Table 4 shows the effect on the calculated results ofTable 3 MIBG and pentetreotide individual lesion uptake
pattern
MIBG + MIBG −
Pentetreotide + 22 8
Pentetreotide − 7 2a
aSeen on CT only.changing normal organ dose limits for a given subject (#8).
As can be seen from this example, reducing the limit for
marrow exposure to 200 cGy from 300 cGy has a notable
effect on the magnitude of the benefit of adding 131MIBG
to PRRT. Specifically, the calculated level of 131I-MIBG ac-
tivity that can be ‘safely’ added to 90Y-DOTATOC drops
from 33.3 to 17.6 GBq for this subject. Accordingly, the
tumor dose benefit drops from 1,493 to 788 cGy. In this
same case, leaving the marrow limit at 300 cGy but increas-
ing the renal dose limit to 2,700 cGy (as some investigators
have suggested is reasonable) has only a small effect on the
calculated results as depicted in the last row of this table.
Discussion
In essence, our methodology and concept boils down to this:
By measuring these following variables for a given patient,
mMIBG =
131I-MIBG red marrow dose per
megabecquerel
mDOTA =
90Y-DOTATOC red marrow dose per
megabecquerel
kMIBG =
131I-MIBG kidney dose per megabecquerel
kDOTA =
90Y-DOTATOC kidney dose per
megabecquerel,
we are able to calculate the optimal amount of 131I-MIBG
to add to the optimal amount of 90Y-DOTATOC that will
Figure 1 Example of discordant 131I-MIBG and 111In-pentetreotide
tumor uptake. SPECT 131I-MIBG (A) and 111In-pentetreotide (B) images
and corresponding CT (C) at the same level from subject #6 showing
a large metastatic lesion that is both MIBG and pentetreotide positive
(thin arrows), along with a metastasis which is MIBG positive and
pentetreotide negative (black circle) and another that is pentetreotide
positive and MIBG negative (thick arrow).
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Furthermore, by measuring these additional patient-specific
variables,
tMIBG =
131I-MIBG tumor dose per megabecquerel
tDOTA =
90Y-DOTATOC tumor dose per megabecquerel,
we are able to calculate the expected increase in tumor
dose, if any, that would occur by adding the calculated
amount of 131I-MIBG to 90Y-DOTATOC.Results of this study strongly support a dosimetric bene-
fit through the addition of 131I-MIBG to 90Y-DOTATOC.
Although this requires the use of patient-specific dosim-
etry measurements, such an approach is consistent with
an ever greater emphasis on individualized medicine. We
have demonstrated that a mathematically definable level
of 131I-MIBG can be added to 90Y-DOTATOC by reducing
the maximum administered activity of 90Y-DOTATOC by
a calculated amount yielding in most cases a substantial
increase in delivered tumor dose while remaining within
specified dose limits for bone marrow and kidneys. We
found this to be the case in five of the ten total subjects
that we studied and in five of the six subjects where MIBG
showed visible tumor uptake. The one case out of these
six where it was not true was somewhat unusual in that
for this patient the kidneys turned out not to be the
dosage limiting organ for 90Y-DOTATOC. In this patient,
bone marrow radiation dose would have limited the
maximum amount of administrable 90Y-DOTATOC.
Specifically, we found that the group median increase in
tumor dose achievable through the addition of 131I-MIBG
was 4,046 cGy and the group mean increase was
8,799 cGy (albeit with a very large standard deviation).
These results are large enough to suggest the potential for
a meaningful amount of additional tumor cell kill.
Our results also corroborate findings from older re-
ports suggesting some differences in tumor targeting
patterns for MIBG versus octreopeptide within the
same patient [20,21,30]. Specifically, we found a clear
evidence of additional tumor site targeting with the
addition of MIBG in four of the ten subjects in our
study, although it should be kept in mind that the
majority of metastatic lesions were positive with both
agents in these four subjects. These results further
support the value of adding 131I-MIBG to the treat-
ment regimen for certain patients receiving PRRT.
Our finding that MIBG is positive overall in 60% of
midgut NET patients is also consistent with other re-
ports [15-17].
The amount of additional 131I-MIBG activity that
could be safely added to 90Y-DOTATOC along with the
required fractional reduction in 90Y activity would
change modestly if different normal organ (kidney and
marrow) dose limits were applied as depicted in Table 3.
For example, if the marrow limit was reduced, the add-
itional amount of 131I-MIBG that could be added would
also be reduced as shown in the table. Although
300 cGy to the marrow would be excessive for a single
treatment, this number is a cumulative limit that would
in practice be achieved through administration of the
treatment drugs over several individual cycles (sepa-
rated by 8 to 12 weeks to allow for marrow recovery).
Going forward, there is also a possibility that normal
organ limits would be better established using the








maximum 90Y activity to be
given when adding MIBG
Acivity (GBq)
of 131I-MIBG that







Kidney 2,300 4.9 75 33.3 1,006 2,499
Marrow 300
Kidney 2,300 4.9 87 17.6 1,006 1,794
Marrow 200
Kidney 2,700 5.8 80 30.8 1,180 2,565
Marrow 300
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consideration for future investigations [31].
Because 90Y is almost entirely a pure beta emitter,
it is quite difficult to obtain pre-therapy biokinetic
imaging measurements for dosimetry calculations using
90Y-DOTATOC itself. Rather, a surrogate radiopharma-
ceutical with very similar pharmacokinetics must be
used in practice. Other radiopharmaceuticals such as
111In-pentetreotide, 111In-DOTATOC, and 86Y-DOTATOC
(PET) have been used as surrogate agents for this purpose
[32,33]. 111In-pentetreotide, the commercially available
agent we used in this project has been found to be a good,
albeit not ideal, dosimetry surrogate for 90Y-DOTATOC
[34]. Importantly, in a study using 86Y-DOTATOC PET as
the gold standard for measuring renal residence times for
90Y-DOTATOC, Helisch and co-workers concluded that
111In-pentetreotide was a reasonable and acceptable surro-
gate for 90Y-DOTATOC when assessing individual patient
pre-therapy renal dosimetry [35].
While the 111In-pentetreotide surrogate approach ap-
pears reasonably good for estimating renal and blood
dosimetry for 90Y-DOTATOC, tumor dosimetry with this
approach is likely somewhat less accurate. Almost cer-
tainly, 111In-pentetreotide tumor dosimetry will under-
estimate the actual delivered dose from 90Y-DOTATOC
[33,36]. This is primarily because DOTATOC shows
greater affinity for the overexpressed SST2 receptor than
does pentetreotide [37]. While this would have an effect
on our calculations of the tumor dose that can be deli-
vered with 90Y-DOTATOC alone, it would not have an
effect on our calculation of the absolute increase in tumor
dose achievable through the addition of 131I-MIBG.
177Lu-DOTATATE is currently undergoing an inter-
national phase 3 trial and may become available for clin-
ical use sooner than the PRRT alternative 90Y-DOTATOC.
There is some evidence that 177Lu-DOTATATE may be
even more effective than 90Y-DOTATOC although the
only comparison of these two agents in the same study
is from a recent retrospective report which found similar
efficacy for the two radioactive drugs [38]. The concept of
a dosimetric benefit through addition of 131I-MIBG to90Y-DOTATOC could, at least qualitatively, be applicable
to 177Lu-DOTATATE as well since the limiting organ for
177Lu-DOTATATE is also the kidney. However, there
would be quantitative differences since renal and tumor
dosimetry for 90Y-DOTATOC and 177Lu-DOTATATE, while
similar, are not the same [39].
There is both pre-clinical and clinical data strongly sup-
porting an enhanced effectiveness for the combination of
177Lu-DOTATOC plus 90Y-DOTATOC which is felt to be
related to the greater spectrum of beta particle energies
achievable when both agents are delivered together leading
to better efficacy for a wider range of tumor sizes [22,40].
Since the beta energy spectrums for 131I and 177Lu are very
similar, such a therapeutic advantage should also exist
for the combination of 131I-MIBG and 90Y-DOTATOC
(EBmax values for 177Lu, 131I, and 90Y are 0.5, 0.6 and
2.3 MeV, respectively).
There are limits to the accuracy of radiopharmaceutical
dosimetry calculations in general and in our study specif-
ically in that we utilized planar rather than SPECT/
CT-based dosimetry for the kidneys and tumors. While
the latter method is generally considered a more accurate
technique for determining dosimetry for single photon
emitters like 131I and 111In, the planar methodology is
nevertheless time-honored and has been used by many
investigators spanning a number of decades to deter-
mine both tumor and kidney dosimetry in studies with
important clinical implications [23,41]. Furthermore,
planar dosimetry measurements for kidneys in particu-
lar should be very reliable because kidneys are relatively
large, usually have minimal overlying activity, and
patient-specific renal mass was utilized in each calcula-
tion in our study. For practical purposes, patient partici-
pation was limited to a 3-day period. Because sampling
was limited to 48 h post-injection, the clearance of the
remaining activity in the tumor and normal tissues after
48 h was estimated from the calculated half time values
from 24 to 48 h. Because of the 67-h half-life of 111In
(and the closely associated 64 half-life of 90Y), this ap-
proach will be reasonably accurate since the physical
half-life would limit any long biologic components. The
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degree, however, because the 8-day half-life would allow
the expression of longer biologic components that were
not sampled.
Nevertheless, it seems persuasive that our dosimetry re-
sults closely approximate those previously reported in the
literature for 131I-MIBG and 90Y-DOTATOC [26,27,29].
Moreover, using an average of previously published
dosimetry values for kidneys and marrow from other
institutions, the calculated activity of 131I-MIBG that
can be added to 90Y-DOTATOC without exceeding
normal organ limits is quite similar to that which we
calculated for the individual patients in our study (see
the last row of Table 2).
Conclusions
We conclude that approximately half of the patients
with midgut NETs that are eligible for PRRT could bene-
fit from the addition of 131I-MIBG to 90Y-DOTATOC.
We believe the next step should be to test this approach
in a phase 1 trial. While there might also be similar bene-
fits for the addition of 131I-MIBG to 177Lu-DOTATATE,
this possibility will require further investigation.
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